Structure Therapeutics Inc (GPCR)
41.92
+3.17
(+8.18%)
USD |
NASDAQ |
Sep 20, 16:00
41.85
-0.07
(-0.17%)
After-Hours: 20:00
Structure Therapeutics Enterprise Value: 1.471B for Sept. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 20, 2024 | 1.471B |
| September 19, 2024 | 1.289B |
| September 18, 2024 | 1.261B |
| September 17, 2024 | 1.272B |
| September 16, 2024 | 1.361B |
| September 13, 2024 | 1.409B |
| September 12, 2024 | 1.377B |
| September 11, 2024 | 1.340B |
| September 10, 2024 | 1.042B |
| September 09, 2024 | 1.087B |
| September 06, 2024 | 1.186B |
| September 05, 2024 | 1.268B |
| September 04, 2024 | 1.239B |
| September 03, 2024 | 1.256B |
| August 30, 2024 | 1.254B |
| August 29, 2024 | 1.265B |
| August 28, 2024 | 1.324B |
| August 27, 2024 | 1.422B |
| August 26, 2024 | 1.395B |
| August 23, 2024 | 1.349B |
| August 22, 2024 | 1.312B |
| August 21, 2024 | 1.340B |
| August 20, 2024 | 1.376B |
| August 19, 2024 | 1.366B |
| August 16, 2024 | 1.196B |
| Date | Value |
|---|---|
| August 15, 2024 | 1.161B |
| August 14, 2024 | 1.146B |
| August 13, 2024 | 1.036B |
| August 12, 2024 | 970.66M |
| August 09, 2024 | 1.004B |
| August 08, 2024 | 1.046B |
| August 07, 2024 | 1.019B |
| August 06, 2024 | 1.082B |
| August 05, 2024 | 1.134B |
| August 02, 2024 | 1.125B |
| August 01, 2024 | 1.157B |
| July 31, 2024 | 1.211B |
| July 30, 2024 | 1.137B |
| July 29, 2024 | 1.335B |
| July 26, 2024 | 1.284B |
| July 25, 2024 | 1.264B |
| July 24, 2024 | 1.146B |
| July 23, 2024 | 1.129B |
| July 22, 2024 | 1.166B |
| July 19, 2024 | 1.214B |
| July 18, 2024 | 1.241B |
| July 17, 2024 | 1.266B |
| July 16, 2024 | 1.627B |
| July 15, 2024 | 1.619B |
| July 12, 2024 | 1.583B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
620.89M
Minimum
May 18 2023
3.241B
Maximum
Oct 31 2023
1.417B
Average
1.266B
Median
Jul 17 2024
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 6.873B |
| Eli Lilly and Co | 855.33B |
| Amgen Inc | 234.58B |
| Pfizer Inc | 228.57B |
| Novo Nordisk AS | 566.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.03M |
| Total Expenses (Quarterly) | 33.32M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -5.30% |